Abstract Details
|
Activity Number:
|
646
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Thursday, August 8, 2013 : 8:30 AM to 10:20 AM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #307897 |
|
Title:
|
Validity of Responder Analysis Using Continuous Endpoints
|
|
Author(s):
|
Davis Gates*+ and Tulin Shekar
|
|
Companies:
|
Merck and Co. and Merck and Co.
|
|
Keywords:
|
responder ;
NNT ;
dichotomizing
|
|
Abstract:
|
In the analysis of clinical trial data, even though dichotomizing continuous outcome data is not a universally accepted practice, it provides a useful tool for clinicians to interpret clinical trials outcomes. In addition, dichotomizing continuous data in preparation for a responder analysis can be used as a tool in clinical trial design. The pros and cons of dichotomizing continuous outcomes are discussed through the use of responder's analysis and numbers needed to treat (NNT's). We will also address the impact on power, sample size, statistical significance and clinical relevance using clinical trials data.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2013 program
|
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.